Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN(a)-Outcomes: Olpasiran (AMG 890) in ASCVD Patients with Elevated Lipoprotein(a)
CTR20232670Phase 3Active
- Sponsor
- Amgen
- Start
- Nov 2023
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of olpasiran in atherosclerotic disease, lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Amgen. Started Nov 2023; status: active.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20232670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232670.